DelveInsight’s “Acute Lymphocytic Leukemia (ALL) – Pipeline Insight, 2026” report provides comprehensive insights about 120+ companies developing over 125 pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the ALL pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Acute Lymphocytic Leukemia treatment landscape. Learn more about the evolving ALL pipeline today @ https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight
Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report
-
On April 6, 2026, the FDA granted Orca-T designations for Orphan Drug, Priority Review, and Regenerative Medicine Advanced Therapy for high-risk hematologic cancers including ALL.
-
On October 9, 2025, Servier initiated a phase 2/3 study to confirm doses and evaluate the safety and pharmacodynamics of Calaspargase pegol for Philadelphia-negative ALL in adults.
-
On October 7, 2025, Amgen announced a Phase 2 study evaluating the efficacy and safety of Blinatumomab in Chinese pediatric subjects with relapsed or refractory B-precursor ALL.
-
On October 7, 2025, M.D. Anderson Cancer Center organized a Phase I/II study combining Blinatumomab and Asciminib for patients with Philadelphia chromosome-positive ALL.
-
On October 6, 2025, Janssen Research & Development initiated a study to determine the recommended Phase 2 dose and safety of bleximenib.
-
Acute lymphocytic leukemia (ALL) is a fast-progressing malignancy characterized by the uncontrolled proliferation of abnormal, immature lymphocytes that replace healthy bone marrow elements.
-
Ascentage Pharma’s Olverembatinib is a leading late-stage candidate, currently undergoing evaluation in Phase III clinical trials as a third-generation tyrosine kinase inhibitor.
-
Hebei Senlang Biotechnology is advancing S1904, a CD19-targeted CAR-T cell therapy, currently in mid-stage clinical evaluation for relapsed or refractory cases.
-
Orca Bio’s Orca-T is in Phase III development, utilizing highly purified regulatory T cells to improve transplant outcomes by preventing graft-versus-host disease (GvHD).
Download for updates and the latest revolution in ALL care @ Acute Lymphocytic Leukemia Market Insight, Epidemiology And Market Forecast
Acute Lymphocytic Leukemia Emerging Drugs Profile
Olverembatinib: Ascentage Pharma
Olverembatinib is a potent, third-generation tyrosine kinase inhibitor (TKI) currently in Phase III clinical development. It is designed to target specific genetic drivers in leukemia, offering a potential therapeutic option for patients who have developed resistance to earlier-generation TKIs. The therapy is part of a growing effort to provide targeted systemic treatments for blood cancers with high unmet needs.
Orca-T: Orca Bio
Orca-T is a high-precision allogeneic cell therapy currently in Phase III development (Precision-T trial) with estimated completion in July 2026. It differs from traditional allogeneic stem cell transplants by including highly purified, polyclonal donor regulatory T cells to prevent GvHD with significantly less immunosuppression. Preliminary Phase Ib/II evidence showed significantly higher GvHD-free and relapse-free survival rates at one year compared to standard nonrandomized comparators.
BEAM-201: Beam Therapeutics Inc.
BEAM-201 is an allogeneic, quad-edited CAR-T cell therapy targeting CD7, currently in Phase I/II clinical evaluation for the treatment of T-cell acute lymphoblastic leukemia (T-ALL). This investigative therapy employs base editing technology to reduce fratricide, prevent graft-versus-host disease, and enable cells to evade anti-CD52 lymphodepletion. By utilizing an allogeneic source, BEAM-201 aims to provide a more readily available “off-the-shelf” treatment option for patients.
For more information on the Acute Lymphocytic Leukemia Emerging Drugs Profile, download DelveInsight’s comprehensive Acute Lymphocytic Leukemia Pipeline Insight report.
The Acute Lymphocytic Leukemia Pipeline Report Provides
-
Detailed insights about companies developing therapies for Acute Lymphocytic Leukemia, with aggregate therapies developed by each company.
-
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for ALL treatment.
-
ALL companies that are involved in targeted therapeutics development with respective active and inactive projects.
-
ALL drugs under development based on stage of development, route of administration, target receptor, and molecular type.
-
Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the Acute Lymphocytic Leukemia market.
Learn more about Acute Lymphocytic Leukemia drug opportunities in our comprehensive ALL pipeline report @ Acute Lymphocytic Leukemia Unmet Needs
Acute Lymphocytic Leukemia Companies and Competitive Landscape
There are 120+ key companies, including Ascentage Pharma, Hebei Senlang Biotechnology, Amgen, Servier, Beam Therapeutics, Janssen, Orca Bio, and others, developing therapies for Acute Lymphocytic Leukemia, with several candidates such as Olverembatinib and Orca-T in the advanced Phase III stage.
DelveInsight’s Acute Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
-
Oral
-
Intravenous
-
Subcutaneous
-
Parenteral
-
Topical
Acute Lymphocytic Leukemia products have been categorized under various Molecule types such as:
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Discover the latest advancements in Acute Lymphocytic Leukemia treatment by visiting our website. Stay informed @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives
Scope of the Acute Lymphocytic Leukemia Pipeline Report
-
Coverage: Global
-
Acute Lymphocytic Leukemia Companies: Ascentage Pharma, Hebei Senlang Biotechnology, Amgen, Servier, Beam Therapeutics, Janssen, Orca Bio, and others.
-
Acute Lymphocytic Leukemia Therapies: Olverembatinib, S1904, Orca-T, BEAM-201, Calaspargase pegol, bleximenib, and other pipeline candidates.
-
Acute Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
-
Acute Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.
Table of Contents
-
Introduction
-
Executive Summary
-
Acute Lymphocytic Leukemia: Overview
-
Pipeline Therapeutics
-
Therapeutic Assessment
-
Acute Lymphocytic Leukemia – DelveInsight’s Analytical Perspective
-
Late Stage Products (Phase III)
-
Mid Stage Products (Phase II)
-
Early Stage Products (Phase I)
-
Preclinical and Discovery Stage Products
-
Inactive Products
-
Acute Lymphocytic Leukemia Key Companies
-
Acute Lymphocytic Leukemia Key Products
-
Acute Lymphocytic Leukemia Unmet Needs
-
Acute Lymphocytic Leukemia Market Drivers and Barriers
-
Acute Lymphocytic Leukemia Future Perspectives and Conclusion
-
Acute Lymphocytic Leukemia Analyst Views
-
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services